Soligenix Advances SGX942 Clinical Program for Oral Mucositis Treatment Following Positive Trial Data
TL;DR
Soligenix's SGX942 offers a competitive edge by potentially becoming the first FDA-approved treatment for oral mucositis, reducing cancer therapy interruptions and hospitalizations.
Soligenix is analyzing combined phase 2 and 3 data for SGX942 to design a second pivotal phase 3 study while seeking development partners for commercialization.
SGX942 improves quality of life for cancer patients by preventing severe oral mucositis, reducing pain and enabling continued nutrition during treatment.
Soligenix develops novel therapies using innate defense regulator technology to treat rare diseases with unmet medical needs like oral mucositis.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX) is analyzing combined phase 2 and 3 clinical datasets to design a second pivotal phase 3 study for SGX942 (dusquetide), its novel therapeutic candidate for oral mucositis, a debilitating side effect of cancer therapy that currently lacks FDA-approved treatments. The company is also actively seeking potential partners to advance this development program, which addresses a critical unmet medical need in oncology supportive care.
Severe oral mucositis (SOM) frequently leads to hospitalization, requires opioid pain management, and necessitates feeding tube placement, substantially reducing patients' quality of life during cancer treatment. These complications often disrupt cancer therapy schedules and compromise patients' ability to maintain nutrition and comfort. The absence of approved treatments makes SGX942's development particularly significant for the oncology community and cancer patients worldwide.
The company's Specialized BioTherapeutics business segment includes multiple development programs, with SGX942 representing its first-in-class innate defense regulator (IDR) technology for inflammatory diseases. Additional information about the company's development programs is available at https://www.Soligenix.com. Soligenix's broader pipeline also includes HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates developed with government support from agencies including the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
The advancement of SGX942 has implications beyond oral mucositis treatment, as successful development could establish a new therapeutic approach for inflammatory conditions. The company's progress in this area represents an important step toward addressing the supportive care needs of cancer patients, potentially improving treatment outcomes and quality of life for those undergoing radiation and chemotherapy.
Curated from InvestorBrandNetwork (IBN)
